From the Guidelines
Trodelvy (sacituzumab govitecan) is indicated for the treatment of adult patients with specific types of cancer, including unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), locally advanced or metastatic urothelial cancer (bladder cancer), and hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. The indications for Trodelvy are based on its approval for these specific cancer types, as it has shown efficacy in treating patients who have received prior therapies for metastatic disease 1. Some key points to consider when prescribing Trodelvy include:
- It is approved for TNBC in patients who have received at least two prior therapies for metastatic disease
- It is approved for locally advanced or metastatic urothelial cancer in patients who previously received platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor
- It is approved for HR-positive, HER2-negative metastatic breast cancer in patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
- The standard dosage is 10 mg/kg administered as an intravenous infusion on days 1 and 8 of 21-day treatment cycles until disease progression or unacceptable toxicity occurs
- Patients should be monitored for potential side effects including neutropenia, diarrhea, nausea, and infusion-related reactions, as reported in recent studies 1.
From the FDA Drug Label
TRADJENTA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1) TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Tradjenta indications are to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise 2, 2, 2.
From the Research
Tradjenta Indications
- Tradjenta, also known as Linagliptin, is indicated for the treatment of adults with type 2 diabetes mellitus 3, 4, 5
- It is used to improve glycemic control in adults with type 2 diabetes mellitus, and can be used as monotherapy or in combination with other antidiabetic agents 3, 4, 5
- Tradjenta is also available in a fixed-dose combination with metformin, known as Jentadueto 3, 4
Patient Population
- Tradjenta can be used in patients with renal impairment, including severe impairment, without the need for dosage adjustment 3, 4, 5
- It can also be used in elderly patients (aged ≥70 years) 3
- Tradjenta has been shown to be effective in patients with type 2 diabetes mellitus, regardless of factors such as age, duration of diabetes, ethnicity, and renal function 4
Comparison with Other Treatments
- Tradjenta has been compared to other treatments for type 2 diabetes mellitus, including GLP-1 receptor agonists and SGLT2 inhibitors 6, 7
- While these treatments have shown efficacy in improving glycemic control and reducing cardiovascular risk, the choice of treatment depends on individual patient factors and needs 6, 7